Pharma Pioneer

Monopar's MNPR-101-Zr Clinical Trial Update

21 May 2024
2 min read

Monopar Therapeutics, a biopharmaceutical firm listed on Nasdaq as MNPR, is advancing its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a potential treatment for advanced cancers. The company has appointed Professor Rodney Hicks, a distinguished expert in radiopharmaceuticals, to spearhead the study. Hicks, who has been instrumental in the approval of radiopharmaceutical agents for various cancers and was honored with the Saul Hertz Award in 2023, will conduct the trial at the Melbourne Theranostic Innovation Centre (MTIC). The trial will employ the Siemens Biograph Vision Quadra, an advanced PET/CT scanner, to assess the drug's targeting capabilities in cancer patients.

Monopar's CEO, Dr. Chandler Robinson, expressed enthusiasm about Hicks' involvement, highlighting his pioneering work in radiopharmaceuticals and his role in establishing the first PET/CT scanner in Australia. Hicks, who is also the founder of MTIC, has a prolific research background with over 650 publications and is committed to facilitating patient access to novel radiopharmaceuticals.

The MNPR-101-Zr drug is under development to address severe medical needs, particularly for pancreatic and triple-negative breast cancers. The clinical trial's Phase 1 dosimetry data and related preclinical findings are accessible online. Monopar Therapeutics is dedicated to creating innovative cancer treatments and has a pipeline that includes camsirubicin for soft tissue sarcoma and an early-stage analog, MNPR-202.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Clears ARTHEx's ATX-01 Phase I-IIa Trial for DM1 Treatment
Pharma Pioneer
3 min read
FDA Clears ARTHEx's ATX-01 Phase I-IIa Trial for DM1 Treatment
21 May 2024
ATHEx Biotech has received approval from the FDA to commence clinical trials for ATX-01, a pioneering microRNA-based treatment for Myotonic Dystrophy Type 1 (DM1).
Read →
CIRM Funds ImmPACT Bio's IMPT-514 CAR T-Cell Therapy for Treating Refractory Lupus
Pharma Pioneer
2 min read
CIRM Funds ImmPACT Bio's IMPT-514 CAR T-Cell Therapy for Treating Refractory Lupus
21 May 2024
ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 1b/2 study of IMPT-514, a novel CAR T-cell therapy.
Read →
Skyhawk Advances SKY-0515 Phase 1 Study to Multiple Ascending Dose for Huntington's Disease Treatment
Pharma Pioneer
3 min read
Skyhawk Advances SKY-0515 Phase 1 Study to Multiple Ascending Dose for Huntington's Disease Treatment
21 May 2024
Skyhawk Therapeutics has made significant progress with its innovative drug candidate, SKY-0515, which is engineered to be an RNA splicing modifier.
Read →
Tonix Concludes Phase 1 Clinical Trial of TNX-1500 in Volunteers
Pharma Pioneer
2 min read
Tonix Concludes Phase 1 Clinical Trial of TNX-1500 in Volunteers
21 May 2024
Tonix Pharmaceuticals Holding Corp. has finished the clinical phase of its Phase 1 trial for TNX-1500, a humanized monoclonal antibody (mAb) designed to prevent organ transplant rejection and treat autoimmune diseases.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.